As a genetic condition, thalassaemia persists across generations without widespread carrier screening and counselling.
While diagnostics and curative options (e.g., HSCT) exist, accessibility remains uneven due to costs, donor limitations, and infrastructural constraints.
Southeast Asia bears a disproportionate burden, with prevalence exceeding 150 per 100,000 in some countries and large case numbers concentrated in the region.
Raise public understanding, reduce stigma, and encourage early screening as a widely accepted norm.
Embed screening and treatment into national health systems, ensuring they are part of long-term care strategies.
Promote the exchange of regional expertise and best practices to monitor progress and inform policy development.